Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.71 USD | 0.00% | +3.18% | +23.67% |
Apr. 19 | Lake Street Starts Cellebrite DI With Buy Rating, $13 Price Target | MT |
Apr. 01 | BofA Securities Adjusts Cellebrite DI Price Target to $13 From $12, Maintains Buy Rating | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Sales forecast by analysts have been recently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 67.25 and 45.08 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Sector: Software
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+23.67% | 2.2B | - | ||
+8.78% | 3,039B | C+ | ||
+2.45% | 80.47B | B | ||
+1.94% | 75.69B | B+ | ||
-16.38% | 54.73B | B+ | ||
-16.33% | 51.62B | B- | ||
+25.74% | 47.77B | D+ | ||
+16.44% | 40.95B | D+ | ||
+56.22% | 35.86B | D+ | ||
-11.26% | 24.36B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CLBT Stock
- Ratings Cellebrite DI Ltd.